Novo Nordisk chairman, independent directors to step down, FT reports

Novo Nordisk (NVO) Chairman Helge Lund and six independent directors are stepping down after a dispute with the Novo Nordisk Foundation, the drugmaker’s majority shareholder, The Financial Times’ Hannah Kuchler reports. “Following dialogue with the Novo Nordisk Foundation regarding the future composition of the board of directors, it has not been possible to reach a common understanding,” Lund said. The foundation is putting forward five candidates for the board, including Lars Rebien Sorensen as chair, and will nominate another two next year, according to the report.